Ontology highlight
ABSTRACT:
SUBMITTER: Su F
PROVIDER: S-EPMC3724537 | biostudies-literature | 2012 Jan
REPOSITORIES: biostudies-literature
Su Fei F Viros Amaya A Milagre Carla C Trunzer Kerstin K Bollag Gideon G Spleiss Olivia O Reis-Filho Jorge S JS Kong Xiangju X Koya Richard C RC Flaherty Keith T KT Chapman Paul B PB Kim Min Jung MJ Hayward Robert R Martin Matthew M Yang Hong H Wang Qiongqing Q Hilton Holly H Hang Julie S JS Noe Johannes J Lambros Maryou M Geyer Felipe F Dhomen Nathalie N Niculescu-Duvaz Ion I Zambon Alfonso A Niculescu-Duvaz Dan D Preece Natasha N Robert Lídia L Otte Nicholas J NJ Mok Stephen S Kee Damien D Ma Yan Y Zhang Chao C Habets Gaston G Burton Elizabeth A EA Wong Bernice B Nguyen Hoa H Kockx Mark M Andries Luc L Lestini Brian B Nolop Keith B KB Lee Richard J RJ Joe Andrew K AK Troy James L JL Gonzalez Rene R Hutson Thomas E TE Puzanov Igor I Chmielowski Bartosz B Springer Caroline J CJ McArthur Grant A GA Sosman Jeffrey A JA Lo Roger S RS Ribas Antoni A Marais Richard R
The New England journal of medicine 20120101 3
<h4>Background</h4>Cutaneous squamous-cell carcinomas and keratoacanthomas are common findings in patients treated with BRAF inhibitors.<h4>Methods</h4>We performed a molecular analysis to identify oncogenic mutations (HRAS, KRAS, NRAS, CDKN2A, and TP53) in the lesions from patients treated with the BRAF inhibitor vemurafenib. An analysis of an independent validation set and functional studies with BRAF inhibitors in the presence of the prevalent RAS mutation was also performed.<h4>Results</h4>A ...[more]